Blueprint Medicines Corp (BPMC)
89.73
-0.99
(-1.09%)
USD |
NASDAQ |
Mar 27, 16:00
89.72
-0.02
(-0.02%)
After-Hours: 20:00
Blueprint Medicines Enterprise Value: 5.506B for March 27, 2025
View 4,000+ Financial Data Types:
Add
Browse
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Biomarin Pharmaceutical Inc | 13.35B |
| Alnylam Pharmaceuticals Inc | 33.42B |
| Palatin Technologies Inc | 15.35M |
| Agios Pharmaceuticals Inc | 848.09M |
| Viking Therapeutics Inc | 2.054B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -49.96M |
| Revenue (Quarterly) | 146.37M |
| Total Expenses (Quarterly) | 187.57M |
| EPS Diluted (Quarterly) | -0.79 |
| Gross Profit Margin (Quarterly) | 94.91% |
| Profit Margin (Quarterly) | -34.13% |
| Earnings Yield | -1.20% |
| Normalized Earnings Yield | -4.231 |